KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Relationship Between Apparent Systemic Clearance of Vemurafenib and Toxicity in Patients With Melanoma.J Clin PharmacolPMID 33908053无 PMCID2021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent.J Clin PharmacolPMID 33908635PMC84571242021-Sep0.98未发现恶性肿瘤人群证据。待处理
Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC.J Thorac OncolPMID 33915251无 PMCID2021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.Lancet Infect DisPMID 33989539无 PMCID2021-Sep0.98未发现恶性肿瘤人群证据。待处理
Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.CephalalgiaPMID 33990144PMC84114642021-Sep0.98未发现恶性肿瘤人群证据。待处理
Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development Neonatal Research Network Randomized Trial.J PediatrPMID 34004189PMC84031382021-Sep0.98未发现恶性肿瘤人群证据。待处理
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).J Thorac OncolPMID 34033974无 PMCID2021-Sep0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial.J Thorac OncolPMID 34033975无 PMCID2021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).J Thorac OncolPMID 34048947无 PMCID2021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.Int J UrolPMID 34075630PMC84537592021-Sep0.98未发现恶性肿瘤人群证据。待处理
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma.Ann OncolPMID 34082019无 PMCID2021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.Cancer Chemother PharmacolPMID 34106303PMC81874582021-Sep0.85The record describes a Phase III randomized trial in HER2-positive early breast cancer with a drug intervention (pertuzumab and trastuzumab). However, the primary analysis is pharmacokinetic and exposure-response (safety and pathologic complete response rate), which are not time-to-event efficacy endpoints (OS, PFS, DFS, etc.). The study lacks a primary or key secondary time-to-event endpoint.待处理
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.Clin Lymphoma Myeloma LeukPMID 34108127无 PMCID2021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.Ann OncolPMID 34116144无 PMCID2021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.AIDS BehavPMID 34117592PMC85779882021-Sep0.98未发现恶性肿瘤人群证据。待处理
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.Ann OncolPMID 34139272无 PMCID2021-Sep0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial.Eur UrolPMID 34140144无 PMCID2021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine.Rheumatol IntPMID 34165604PMC83162262021-Sep0.98未发现恶性肿瘤人群证据。待处理
A medicine adoption model for assessing the expected effects of additional real-world evidence (RWE) at product launch.Curr Med Res OpinPMID 34176383无 PMCID2021-Sep0.98未发现恶性肿瘤人群证据。待处理
Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19.Adv Sci (Weinh)PMID 34180141PMC84203762021-Sep0.98未发现恶性肿瘤人群证据。待处理
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.Cancer Commun (Lond)PMID 34184418PMC84410572021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy of ready-to-use therapeutic food in malnourished children with cancer: Results of a randomized, open-label phase 3 trial.Pediatr Blood CancerPMID 34212474无 PMCID2021-Sep0.95The study is a randomized Phase III trial in pediatric cancer with original results, but it evaluates a nutritional intervention (RUTF), not a drug, and its primary/secondary outcomes are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analyses).待处理
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.Eur J CancerPMID 34225066无 PMCID2021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.Thorac CancerPMID 34273139PMC84105522021-Sep0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.Eur J CancerPMID 34273811无 PMCID2021-Sep0.95This is an analysis of health-related quality of life outcomes from the ARAMIS trial. While the parent trial was a Phase III randomized trial with a drug intervention and MFS/OS as primary/key secondary endpoints, this specific report focuses solely on patient-reported quality-of-life endpoints (time to deterioration on FACT-P and EORTC QLQ-PR25). It is therefore a quality-of-life analysis and does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint for inclusion.待处理
Economic Impact of Preoperative Meloxicam IV Administration in Total Knee Arthroplasty: A Randomized Trial Sub-Study.J Pain Palliat Care PharmacotherPMID 34280067无 PMCID2021-Sep0.98未发现恶性肿瘤人群证据。待处理
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.Lancet Respir MedPMID 34280355无 PMCID2021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Diabetes EndocrinolPMID 34302745PMC82948072021-Sep0.98未发现恶性肿瘤人群证据。待处理
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.Eur J CancerPMID 34304054无 PMCID2021-Sep1.00命中用户提供的消化道肿瘤阳性参考集。待处理
Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.Lancet OncolPMID 34329606PMC84167992021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.Nat MedPMID 34341578无 PMCID2021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.Lancet OncolPMID 34363762无 PMCID2021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network.Eur J CancerPMID 34371442无 PMCID2021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial.J Gynecol OncolPMID 34378365PMC83628162021-Sep0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.Am J Clin DermatolPMID 34406619PMC83708592021-Sep0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。待处理
Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo-controlled multicentre trial.United European Gastroenterol JPMID 34414678PMC84352582021-Sep0.98未发现恶性肿瘤人群证据。待处理
Effects of Fixed-dose Combination of Low-intensity Rosuvastatin and Ezetimibe Versus Moderate-intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-blind, Multicenter, Phase III Study.Clin TherPMID 34429197无 PMCID2021-Sep0.98未发现恶性肿瘤人群证据。待处理
Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.Lancet HaematolPMID 34450102无 PMCID2021-Sep0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial.Paediatr DrugsPMID 34462864PMC84185912021-Sep0.98未发现恶性肿瘤人群证据。待处理
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.Contemp Clin TrialsPMID 34538402PMC85209132021-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.RMD OpenPMID 34548383PMC84583212021-Sep0.98未发现恶性肿瘤人群证据。待处理
A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study).Jpn J Clin OncolPMID 34215870无 PMCID2021-Aug-300.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.Jpn J Clin OncolPMID 34322703PMC84058452021-Aug-300.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A pilot feasibility study of gabapentin for managing pain in children with dystonic cerebral palsy.BMC PediatrPMID 34454442PMC84011812021-Aug-280.98未发现恶性肿瘤人群证据。待处理
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.J Hematol OncolPMID 34454540PMC84013382021-Aug-280.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.LancetPMID 34454674无 PMCID2021-Aug-281.00命中用户提供的消化道肿瘤阳性参考集。待处理
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis.Nephrol Dial TransplantPMID 33629100无 PMCID2021-Aug-270.98未发现恶性肿瘤人群证据。待处理
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).Nephrol Dial TransplantPMID 33630072PMC83975112021-Aug-270.98未发现恶性肿瘤人群证据。待处理
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.N Engl J MedPMID 34437784PMC89821852021-Aug-260.98未发现恶性肿瘤人群证据。待处理
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.Arthritis Res TherPMID 34429160PMC83834192021-Aug-240.98未发现恶性肿瘤人群证据。待处理